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Abstract
In recent years, technological advances have enabled a detailed landscaping of the epigenome and the mechanisms of epigenetic
regulation that drive normal cell function, development and cancer. Rather than merely a structural entity to support genome
compaction, we now look at chromatin as a very dynamic and essential constellation that is actively participating in the tight
orchestration of transcriptional regulation as well as DNA replication and repair. The unique feature of chromatin flexibility
enabling fast switches towards more or less restricted epigenetic cellular states is, not surprisingly, intimately connected to cancer
development and treatment resistance, and the central role of epigenetic alterations in cancer is illustrated by the finding that up to
50% of all mutations across cancer entities affect proteins controlling the chromatin status. We summarize recent insights into
epigenetic rewiring underlying neuroblastoma (NB) tumor formation ranging from changes in DNA methylation patterns and
mutations in epigenetic regulators to global effects on transcriptional regulatory circuits that involve key players in NB onco-
genesis. Insights into the disruption of the homeostatic epigenetic balance contributing to developmental arrest of sympathetic
progenitor cells and subsequent NB oncogenesis are rapidly growing and will be exploited towards the development of novel
therapeutic strategies to increase current survival rates of patients with high-risk NB.
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Introduction
The ‘Hallmarks of Cancer’ concept as proposed by Hanahan
andWeinberg has provided a framework to understand the com-
plex principles of cancer biology (Hanahan andWeinberg 2000,
2011). These hallmarks explain how cancer cells breach multi-
ple cellular safeguards driving proliferation and self renewal,
unlimited growth, angiogenesis, invasion and metastasis and
evasion of cell death, maintenance of genomic stability,
sustained energy supply related to the rewired metabolic cancer
cell circuitry and tumor promoting inflammation (Hanahan and
Weinberg 2011). In the past decade, altered epigenetic states,
with a main focus on promotor hypermethylation coupled to
inactivation of tumor suppressor genes, were already recognized
to play a major role in many cancer entities. Recently, a bewil-
dering number of mutations were found that affect the
expression/function of a wide variety of proteins involved in
chromatin modification as well as local and higher-order chro-
matin structure. In addition, there is increasing evidence that
malignant transformation inmany different tumor types depends
on the formation of super-enhancer-driven core regulatory
circuits. Last, a vast majority of transcriptional states is not only
instructed through the action of regulatory proteins but also
relies on protein/non-coding RNA interactions. This has dra-
matically fueled ongoing fundamental and translational epige-
netic cancer research, together with the notion that these
perturbed epigenetic states present a novel target for therapy.
Neuroblastoma (NB) is considered as a developmental dis-
order resulting from the disruption of normal sympathetic
neuronal progenitor maturation. Furthermore, like most other
pediatric cancers, the mutational landscape at diagnosis is rel-
atively silent with an average of only 5–10 mutations.
Therefore, it can be assumed that deviation from the normal
epigenetic homeostasis during this process could play a key
role in malignant transformation. While the basic concepts of
the ‘epigenetic landscape’ explaining the underlying process-
es of normal cell differentiation were proposed more than
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50 years ago by Conrad Waddington, we have now learned
that (1) transcription factors are key actors in establishing and
guiding cellular identity (reflecting the developmental
grooves going down the developmental Waddington hill)
while interacting with various DNA regulatory elements em-
bedded in a specific epigenetic constellation, and (2) chroma-
tin ensures the stability of these lineages and cell fates (the
depth of the grooves on the hill). In a recent review, Flavahan
et al. proposed the concept of abnormal epigenetic resistance
and plasticity resulting from altered chromatin regulator activ-
ity and remodeling as well as DNA methylation as important
processes taking part in tumorigenesis (Flavahan et al. 2017).
We propose that a full understanding of the epigenetic con-
trol of normal sympathetic neuron differentiation and
uncovering the key epigenetic perturbations during NB devel-
opment will be instrumental to fully understand the molecular
basis of NB oncogenesis.Moreover, given the limited number
of mutated druggable targets, these insights can also guide us
towards the development of novel therapeutic interventions to
increase survival rates and reduce long-term effects of current
cytotoxic treatment.
Knowledge from different ongoing research efforts may
converge towards this goal, e.g., novel neural crest or sympa-
thetic progenitor cell-derived NB models, as nicely illustrated
with the recently developed model system by Olsen and col-
leagues allowing ex vivo generation of MYCN-driven trans-
formed neural crest stem cells to be transplanted into recipient
mice, leading to tumor formation consistent with our under-
standing of human MYCN-driven NB and thus providing an
excellent toolkit for the discovery of novel driver genes in this
malignancy (Olsen et al. 2017). Among others, transcription
factors that are key in normal neuronal development (e.g.,
SOX11, TWIST1 and TCF3) as well as cell cycle regulators
(FOXM1, E2F3 and MYBL2) were found to be upregulated
in this experimental murine NB model in accordance with
human NB tumors. Future studies should provide further in-
depth profiling of epigenetic landscaping in cellular models
and primary tumors including enhancer mapping, screening
for gene essentiality or cancer dependency, and further in-
depth bioinformatics analyses of developmental and gene reg-
ulatory networks in large transcriptome and proteome datasets.
Ultimately, this should guide us towards exploiting the epige-
netics toolbox to develop more effective and less toxic thera-
pies in combination with other small molecules (e.g., ALK
and/or RAS/MAPK inhibitors) and immunotherapy to reach
the full extent of precision medicine for these patients.
Mapping of neuroblastoma-specific
epigenetic DNA modifications
DNA methylation is a stable epigenetic modification of
which the global pattern can be faithfully inherited through
multiple cell divisions. During development and cell dif-
ferentiation, DNA methylation is dynamic, but some pat-
terns may be retained as a form of epigenetic memory,
while cancer initiation and progression can lead to
genome-wide and gene-specific DNA methylation chang-
es. Methylation states can thus inform both on oncogenic
altered epigenetic states of genes as well as a cell-of-origin
epigenetic profile (Feinberg et al. 2016). For a detailed
overview of the most prominent DNA methylation markers
in neuroblastoma, see the review by Decock et al. (2011).
Methylation and prognostic classification
Like for many other tumor entities, several studies focusing
on methylation have been conducted in NB, using increas-
ingly more powerful and sensitive methods. One of the first
prognostic methylation studies was reported by Alaminos and
co-workers who investigated promoter hypermethylation in
45 candidate genes in 10 NB cell lines and a subsequent
selection of 10 genes in 118 primary NBs by means of
methylation-specific PCR (MSP). This CpG island hyperme-
thylation portrait showed distinct patterns for MYCN-ampli-
fied versus non-amplified tumors, among others for the tumor
suppressor caspase-8 (Alaminos et al. 2004). Hoebeeck et al.
used the same technique to screen the methylation status of
10 selected tumor suppressor genes in 33 NB cell lines and 42
primary NB cases (Hoebeeck et al. 2009). In follow-up of
MSP, novel techniques have been developed allowing
genome-wide analysis of aberrant DNA methylation patterns,
such as various methylation arrays. This also included
methyl-CpG-binding domain (MBD) sequencing of NB cell
lines, a sensitive and cost-effective method for genome-wide
DNA methylation profiling and biomarker identification.
Using this method in combination with MSP on primary
NB tumors, eight candidate biomarkers (Decock et al.
2012) were identified of which the methylation status could
be related to previously known risk factors such as age and
MYCN amplification status, underscoring the prognostic val-
ue of these methylation markers. Later on, we expanded this
work byMBD-sequencing based screening of 87 primary NB
tumors in search for methylation biomarkers relating to event-
free and overall patient survival rates, followed by validation
using MSP assays in independent cohorts of 132 and 177
tumor samples. As such, Decock and co-workers established
a prognostic DNA methylation signature consisting of 58
markers which allowed accurate outcome prediction in the
total NB patient cohort; additionally, we revealed a novel
specific characteristic of 4S NB tumors (Decock et al.
2016a, b, c). In brief, it was shown that specific chromosomal
regions could be identified to be uniquely hyper- or
hypomethylated in stage 4S tumors compared to the other
stages, comprising genes implicated in neuronal differentia-
tion (e.g., targets of MSX1 and GFI1) among others, as well
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as genes located on subtelomeres. Based on these findings, it
was hypothesized that subtelomeric DNA methylation repre-
sents an additional mechanism by which telomere length and
spontaneous regression are controlled in NB. A similar study
by Olsson et al. (2016) compared high- versus low-grade NB
tumors using the Infinium Human Methylation 450 k
(HM450K) BeadChip. Screening of 60 primary neuroblasto-
ma cases revealed, among others, that the TERT gene is one
of the strongest hypermethylated genes in high-risk versus
low-risk tumors and that this change in the epigenetic state
of TERT could be clearly linked to altered expression corre-
lating to poor patient survival.
More recently, novel methods for genome-wide methyla-
tion analysis (e.g., 450 k array) resulted in more comprehen-
sive analyses. The Westermann team applied an integrative
approach to analyze the methylomes, transcriptomes, and
copy number variations of 105 NB cases, complemented by
primary tumor- and cell line-derived global histone modifica-
tion analyses and epigenetic drug treatment in vitro (Henrich
et al. 2016). This investigation further supported the presence
of distinct DNA methylation patterns identifying divergent
patient subgroups, with respect to survival and clinical/
biological variables, including MYCN amplification. Similar
observations were reported by Gomez et al. based on an
Infinium Human Methylation 450 k (HM450K) BeadChip
analysis of 35 primary NB cases (Gomez et al. 2015). In
addition, non-CpG methylation was also observed and mostly
associated with tumors characterized by favorable clinical-
biological features.
CpG island hypermethylation
Henrich et al. (2016) also investigated and confirmed the
previously proposed CpG island methylator phenotype
(CIMP) association with gene body methylation of
protocadherin beta family (PCDHB) members in high-risk
associated NB (Abe et al. 2005, 2007). Transcriptome inte-
gration and histone modification-based definition of enhanc-
er elements revealed intragenic enhancer methylation as a
mechanism for high-risk associated transcriptional deregula-
tion. In this same study, the most prominent high-risk asso-
ciated phenomenon was hypermethylation in combination
with transcriptional downregulation of genes enriched for
1p36 genes, including the well-established dosage-dependent
NB suppressor candidates, CAMTA1, CHD5 and KIF1B
(Henrich et al. 2012) (see Fig. 1). This finding suggested that
DNA methylation could further reduce expression levels of
tumor suppressors of which one allele is deleted. Finally,
evidence was also presented for cooperation between the
‘Polycomb Repressive Complex’ (PRC2) (see below) activ-
ity and DNA methylation in blocking tumor-suppressive dif-
ferentiation programs.
Altered methylation profiles underlying
differentiation therapy
The stage 4S NB phenotype has spurred investigations
towards differentiation therapy and led to the integration
of retinoic acid (ATRA) administration in particular thera-
py schemes. The molecular basis of the effects of ATRA in
NB are still poorly understood, but (partial) epigenetic
resetting towards the normal chromatin state and subse-
quent altered expression patterns can be assumed to be
the underlying driving effector. In this perspective, the
Stallings team applied genome-wide DNA methylation
analysis to study epigenetic modifications during ATRA-
induced neuroblastoma differentiation (Stallings et al.
2011) using an ATRA-sensitive neuroblastoma cell line.
In total, 402 and 88 gene promoters were found to be
hypo- and hypermethylated, respectively. Subsequent inte-
gration with mRNA expression data revealed that 82
hypomethylated genes were over-expressed (>2-fold) and
13 hypermethylated genes were under-expressed (>2-
fold), indicating that many of the DNA methylation alter-
ations had functional consequences. Further investigation
towards the underlying mechanism revealed a statistically
significant decrease in expression of both DNMT1 and
DNMT3A upon ATRA treatment, possibly mediated
through altered expression levels of miRNAs targeting
mRNA stability or translation of these important DNA
methylases. Later on, the same research team performed
methylated DNA immunoprecipitation coupled to custom
tiling array hybridization for 18 primary neuroblastoma
tumors and 3 neuroblastoma cell lines to screen the meth-
ylation status of 528 miRNA loci (Das et al. 2013). In
total, 67 miRNAs were found to be lower expressed
(hypermethylated) in neuroblastomas compared to con-
trols, several of which are involved in regulation of cellu-
lar differentiation.
Global hypomethylation
Besides the phenomenon of localized hypermethylation at
CpG sites, Feinberg and Vogelstein discovered that also a
genome-wide loss of DNA methylation (Feinberg and
Vogelstein 1983) (see Fig. 1) at non-CpG sites contributes
to the process of malignant transformation, mainly through
aberrant oncogene activation and genomic instability, the
latter inferred by the fact that these sites often serve as
hotspots of chromosomal breaks. Mayol et al. (2012) used
the ‘Infinium Human Methylation27 BeadChip’ platform
to generate genome-wide DNA methylation profiles from
22 primary NB cases and bisulfite sequencing for an inde-
pendent cohort of 13 cases, to show that in primary NBs
promoter hypermethylation is a more restricted phenome-
non compared to gene-specific DNA hypomethylation.
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The latter was found not only to occur at promoter regions
but also at more distal regulatory sites, in agreement with
the later finding by the same research team that DNA
methylation depletion at distal sites of the CCND1 NB
Fig. 1 Overview of the epigenetic rewiring events that underlie NB tumor formation. Proteins in green: epigenetic modifiers that are overexpressed in
NB cells; proteins in pink: epigenetic modifiers that are downregulated in NB cells through genetic aberrations
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oncogene are key to drive its overexpression in NB
(Gomez et al. 2015).
Active DNA demethylation – 5-hydroxymethylation
Initially, cytosinemethylation was considered as a stable mod-
ification. It is now known that also DNA demethylation can
take place and also plays an important role in normal devel-
opment and cancer, underlying genomic instability (Jeschke
et al. 2016). Demethylation of the DNA template can occur
either actively or passively. Passive DNA demethylation can
occur during DNA replication. Instead, active DNA demeth-
ylation is a consequence of the catalytic activity of the ‘Ten
Eleven Translocation’ (TET) protein family (TET1, TET2,
TET3). These TET enzymes convert 5-methylcytosine
(5mC) to the intermediate 5-hydroxymethylcytosine
(5hmC), which can be further oxidized to 5-formylcytosine
and 5-carboxylcytosine (Delatte et al. 2014). These oxidation
products can then be efficiently removed from the DNA tem-
plate by the activity of the ‘thymine DNA glycosylase’ en-
zyme and replaced by an unmethylated cytosine residue dur-
ing DNA repair (base excision repair). The role of 5hmC is
also firmly established in the context of differentiation of var-
ious tissues, for example, with strong enrichment of this mod-
ification in neuronal tissue (Hahn et al. 2013) and high levels
in pluripotent cells (Choi et al. 2014). Mariani et al. (2014)
related global increases in 5hmC in NB to the response on
hypoxia. Taking into account that neuronal tissue harbors
high levels of 5hmC and that neuroblastoma cells undergo
dedifferentiation in hypoxic conditions, 5hmC levels could
be involved in regulation of differentiation stage transi-
tions of NB tumor cells.
Histone modifier enzymes as novel players
in NB tumor development
In addition to DNA methylation, a second major layer of epi-
genetic information is dictated by a series of post-translational
modifications (PTMs) at the N-terminal tails of the core his-
tone proteins (H2A, H2B, H3, H4 and linker histone H1) to
form the so-called ‘histone code (Strahl and Allis 2000). In
addition, a variety of histone variants can replace the canoni-
cal ones, such as the H2Avariant H2AX, which is incorporat-
ed into the nucleosomes at sites where DNA double-strand
breaks occur (van Attikum and Gasser 2009) or the histone
H3 variant H3.3, that specifically associates with sites of ac-
tive transcription and affecting transcriptional plasticity as
well as playing a key role in the process of tumorigenesis
(Yuen and Knoepfler 2013). There are at least eight different
types of PTMs possible on histone tails, such as lysine acety-
lation, lysine and arginine methylation, serine and threonine
phosphorylation among others, that can be of different forms
(e.g., di- or tri-methylation) (Kouzarides 2007). Particular
modifications can mark regions of active or inactive transcrip-
tion. Importantly, histone modifications are also specific in
demarcating various functional elements in the genome such
as enhancers or transcribed regions (Zhou et al. 2011). Histone
modifications are dynamic in nature, and a plethora of histone
modifier enzymes has been identified in the last decades that
are involved in the deposition (‘writers’) or removal of the
histone PTMs (‘erasers’). A third class of proteins can dock
to certain histone modifications through a specific binding
domain, but have no intrinsic enzymatic activity (‘readers’)
and act to recruit writers and erasers for control of the expres-
sion of target genes. For example, the plant homeodomain
pocket is one of the most commonly found domains enabling
histone methyl-lysine binding.
Histone acetyltransferases/deacetylases
(HATs/HDACs)
One of the most prominent members of the ‘writer/eraser’
class of histone modifier enzymes are the histone acetyltrans-
ferases (HATs)/deacetylases (HDACs), serving as an impor-
tant switch between repressive and permissive chromatin
states. Both HATs and HDACs serve as co-factors, implying
that they are recruited by other DNA-binding factors to the
site-of-action rather than associating themselves with the
DNA template. Three main types of HATs (the GNAT5,
CBP/p300 and MYST subfamilies) (Gajer et al. 2015) and
18 different HDAC proteins (Ropero and Esteller 2007) can
be distinguished in mammalian cells. One of the most prom-
inent HATs is CBP/p300 (see Fig. 1), expressed in many
different tissue types and implicated in the regulation of var-
ious normal cellular processes such as cell cycle regulation
and differentiation (Sterner and Berger 2000), but also a
known player in malignant transformation either as a tumor
suppressor or supporting the action of specific oncogenes
(Goodman and Smolik 2000). Altered HDAC expression
has been reported in NB (West and Johnstone 2014).
Oehme et al. (2009a, b) screened the expression of human
the HDAC family in a primary NB cohort of 251 patients by
micro-array based profiling and an independent cohort of 118
samples by real-time RT-PCR and found that HDAC8 over-
expression significantly correlated to poor patient prognosis.
In keeping with this finding, Rettig and colleagues demon-
strated in vitro and in vivo potency of selective HDAC8
inhibitors for NB treatment (Rettig et al. 2015) (see Fig. 1).
In addition, the key neuroblastoma driver oncogene MYCN
has been shown to cooperate with HDAC proteins during
malignant transformation to repress its target genes, e.g., with
HDAC5 in the silencing of CD9 (Fabian et al. 2016), with
HDAC2 to downregulate the expression of the tumor sup-
pressor miRNA-183 (Lodrini et al. 2013) and with HDAC3
in silencing of GRHL1 (Fabian et al. 2014).
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Histone methyltransferases/demethylases
(HMTs/HDMs)
The second type of enzymes that can influence the histone
code are the histone methyltransferases (HMTs) and his-
tone demethylases (HDMs). Histone methylation can either
be placed on lysine or arginine residues and is executed by
proteins (total of 48 in mammalian cells) containing a ‘sup-
pressor of variegation’ (SET) domain (Albert and Helin
2010), with DOT1L being the only member not containing a
SET pocket. For the latter, Wong et al. (2017) very recently
described a role in NB tumorigenesis together with MYCN in
downstream target activation, due to its unique capacity of all
HMTs to catalyze methylation of H3K79 (see Fig. 1). In ad-
dition, the expression of DOT1L itself was also driven by
MYCN and its high levels in neuroblastoma tumors were
shown to correlate with poor survival. Application of a
DOT1L inhibitor proved antitumorigenic potential both
in vitro and in neuroblastoma xenografts, indicating the ther-
apeutic potential for treatment of MYCN-driven NB tumors.
Besides H3K79 methylation, H3K4me3 is also an established
epigenetic mark for permissive gene expression. Among
others, WDR5 is a core component of the H3K4me3 writer
complex MLL–SET1 (see Fig. 1) and is known to function as
a key co-factor of the MYC oncoprotein in cancer (Thomas
et al. 2015). In NB, similar to DOT1L, WDR5 expression
levels are upregulated by MYCN and indicate poor survival
changes in primary cases. The formation of a transcriptional
complex between MYCN and WDR5 leads to downstream
target activation, such as the anti-apoptotic factor MDM2
(Sun et al. 2015). Very recently, Veschi and co-workers per-
formed a high-throughput screening strategy combining
RNAi (siRNAs) for 400 genes and 21 epigenetic chemical
probes (Veschi et al. 2017) to identify epigenetic modulators
that suppress NB cell differentiation. From this screen, the
H4K20 methyltransferase SETD8 was identified as a top can-
didate (see Fig. 1), with high SETD8 levels in primary NB
tumors correlating to poor patient prognosis. Genetic and
pharmacological perturbation of SETD8 resulted in a signifi-
cant reactivation of p53 signaling, inducing a pro-apoptotic
and antiproliferative response both in vitro and in vivo, the
latter underscored by a significant reduction of murine xeno-
graft tumor growth.
In contrast to H3K79 and H3K4 methylation which are
associated with gene activation, methylation of other lysine
residues of histone H3/4 such as K9 or K27 induces tran-
scriptional silencing. The G9a H3K9 methyltransfersase
was shown by Ke and colleagues to fulfill an oncogenic
role in NB development by epigenetic regulation of
autophagosome formation and pinpoint G9a as a novel
potent NB therapeutic target (Ke et al. 2014). The forma-
tion of H3K27me3 is catalyzed by PRC2, a multi-subunit
assembly that is essential during normal embryonic
development (Hock 2012). The catalytic component of
PRC2 is the ‘Enhancer of Zeste’ (EZH2) protein (see Fig.
1) and its efficiency requires the action of the co-factors
EED and SUZ12. In cancer, PRC2 may act either as an
oncogene or tumor suppressor, depending on the cellular
context and tumor type. In its association with the co-factor
MAX and the aforementioned histone methyltransferase
WDR5, MYCN is acting as a transcriptional activator. Its
role as a transcriptional regulator has now proven to be
dual, and MYCN is equally capable of repressing a subset
of its downstream target genes, predominantly involved in
neuronal differentiation (Gherardi et al. 2013). In this con-
text, MYCN has been shown to physically interact with
PRC2 (Corvetta et al. 2013; He et al. 2013), although fur-
ther research will be required to show what the functional
importance of this interaction is in the context of MYCN
regulated gene expression programs. In NB, MYCN-
amplified tumors show a ‘PRC2 hyperactivation’ profile,
exhibiting very strong expression levels of the PRC2 com-
ponents, EZH2, EED and RBBP7, versus non-amplified
NB tumors (Henrich et al. 2016). This leads to a significant
enrichment of H3K27me3 signal for a set of genes of
which hypermethylation and concomitant downregulated
expression is associated with high-risk NB. In addition,
Wang and colleagues have previously shown that EZH2
overexpression in NB is related to poor patient prognosis
and that PRC2 suppresses differentiation through epigenet-
ic silencing of tumorsuppressor genes like CASZ1 (Wang
et al. 2012). It was previously shown that MYC is respon-
sible for direct upregulation of EZH2 expression and that
MYCN could act likewise in the context of NB (Neri et al.
2012; Tsubota et al. 2017). Recently, Bate-Eya et al. (2017)
suggested that the recurrent gain of the EZH2 locus could
contribute to its overexpression. Notably, the survival ad-
vantage hereby conferred to NB cells was shown to be
independent of its catalytic activity but rather caused by a
so far uncharacterized non-canonical EZH2 function.
Therefore, in NB, the application of drugs inhibiting
EZH2 activity might be required to be directed to the com-
plete protein functionality rather than a moiety targeting
only its catalytic pocket, which will require further
investigation.
Besides EZH2 as part of the PRC2 complex, the PRC1
component BMI1 also has an established role in NB develop-
ment. The PRC1 complex can either be recruited to its target
genes by K27me3 modifications imposed on the chromatin
template by PRC2, or can also bind independently of PRC2
(Hock 2012). The PRC1 core component BMI1 (see Fig. 1)
is overexpressed in as much as 90% of neuroblastoma cases
(Huang et al. 2011), and has been shown by Cui et al. (2007)
to be a cooperative oncogene in MYCN-driven NB. Its over-
expression (together with MYCN) can be driven by E2F1
(Nowak et al. 2006), but in addition MYCN itself can also
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induce high BMI1 expression levels in NB cells (Ochiai et al.
2010), with concomitant inhibition of cell death and differen-
tiation through inhibition of tumor suppressor gene expression
(e.g., KIF1ß).
A key lysine demethylase implicated in NB is LSD1
(KDM1A). The LSD1 protein specifically catalyzes demeth-
ylation of H3K9me1/2 and H3K4me1/2 (Hosseini and
Minucci 2017) (see Fig. 1) and plays essential functions dur-
ing normal development (e.g., embryogenesis) as well as ma-
lignant transformation, with high LSD1 levels being observed
in many different cancer types (Zheng et al. 2015). In NB,
elevated LSD1 expression was shown to be correlated with
adverse outcome and inversely correlated with differentiation
in neuroblastic tumors. LSD1 depletion decreased cellular
growth, induced expression of differentiation-associated
genes, and increased target gene-specific H3K4 methylation
and reduced neuroblastoma xenograft growth in vivo.
Subsequently, miRNA-137 was identified as a LSD1 negative
upstream regulator and a novel tumor suppressor in NB de-
velopment, with downregulation of LSD1 mimicking
miRNA-137 re-expression in neuroblastoma cells (Althoff
et al. 2013). More recently, Amente et al. (2015) revealed a
functional cooperation of LSD1with the central NB oncogene
MYCN through a physical interaction, supporting a tran-
scriptional repressor role of MYCN, among others, facili-
tating silencing of NDRG1, a tumor suppressor gene normally
suppressing NB cell motility and invasion capacity (Ambrosio
et al. 2017). Also, the H3K9me2/3 demethylase KDM4B was
recently identified as another novel MYCN interaction partner
in NB, assisting in sustaining tumorigenesis (Yang et al.
2015). These results thus indicate the therapeutic value of
combined MYCN–KDM pharmacological inhibition.
Chromatin remodeling complexes
Chromatin remodeling complexes are a specific type of regu-
lators catalyzing the eviction or deposition of nucleosomes
coupled to ATP hydrolysis, consisting of: the ‘Switching
defective/Sucrose Non-Fermenting’ (SWI/SNF) family,
‘Inositol requiring 80’ (INO80), ‘Imitation Switch’ (ISWI)
and the ‘Chromodomain Helicase DNA binding’ (CHD) fam-
ily (Clapier and Cairns 2009).
From the latter class, the ATP-dependent helicase CHD5
(see Fig. 1) has been proposed as a key tumor suppressor gene
(Bagchi et al. 2007) targeted by deletion of 1p36 in high-risk
(often MYCN-amplified) neuroblastomas. Low CHD5 levels
are associated with poor patient prognosis. Alternatively,
high-risk NB patients can also present with CHD5 distal pro-
moter methylation (Koyama et al. 2012; Fujita et al. 2008),
further supporting a tumor suppressor role of CHD5 in NB
tumor development. High CHD5 levels can be found in the
brain and to a lesser extent in the adrenal glands (Thompson
et al. 2003), underscoring its importance in normal neuronal
development and neuronal differentiation downstream of
TRKA (Higashi et al. 2015) as part of a ‘nucleosome remod-
eling and deacetylation’ (NurD) protein complex (Potts et al.
2011). To execute its function, CHD5 associates with the
NurD complex, leading to the formation of a transcriptional
repressor complex dampening the expression of the G2/M
checkpoint kinase WEE1 (Quan et al. 2014). Additionally,
several oncogenic miRNAs downstream (e.g., miRNA-204)
of MYCN have been identified to reduce CHD5 expression
in NB tumors (Naraparaju et al. 2016). Furthermore, the role
of CHD5 as a tumor suppressor is also well established in
other tumor entities, such as glioma, breast and colon cancer
(Kolla et al. 2014).
The SWI–SNF complex fulfills key tasks during normal
mammalian development, with evidence for a role in heart
and muscle development, neuronal development and hemato-
poiesis (Cedar and Bergman 2011). Mechanistically, the
SWI–SNF remodeler subunits have an important role in nu-
cleosome eviction to allow for transcriptional activation and
elongation by POLII (Subtil-Rodriguez and Reyes 2010;
Schwabish and Struhl 2007). The complex is structurally con-
served and the components that drive its remodeler activity are
part of the core, whereas other constituents are rather tissue-/
context-specific (Tang et al. 2010). In total, this combinatorial
complexity leads to over 100 different possible assemblies
(Ho and Crabtree 2010). This diversification in composition
also occurs during neuronal development (Lessard et al.
2007), with stage-specific changes, e.g., from embryonic stem
cells to neuronal progenitor cells (Son and Crabtree 2014).
From the subunits conferring functional specificity, ARID1A
is known, together with ARID1B, as a subunit specific to the
‘BAF’-type SWI–SNF complex and is one of the most com-
monly mutated subunits in cancer (Shain and Pollack 2013).
Overall, one-fifth of all human tumors exhibit mutations in
SWI–SNF complex components, demarcating it as the most
frequently mutated epigenetic regulator complex and
underscoring a critical tumor suppressor role for its constitu-
ents in various human cancer types (Kadoch et al. 2013). In
pediatric cancer entities, the crucial role of the complex is
underscored by the fact that atypical teratoid/rhabdoid tumors
(ATRT) can be divided into three molecular epigenetic
subytpes, but with no other recurrent mutations found by ex-
ome sequencing besides those found in the SMARCB1 gene
(Johann et al. 2016). Awhole genome and exome sequencing
effort by Sausen and colleagues revealed ARID1A/B
mutations (see Fig. 1) and deletions in 11% of neuroblastoma
cases (Sausen et al. 2013), and targeted sequencing performed
by Lee et al. confirmed that cases with ARID1B mutations
present with high-risk NB (Lee et al. 2017). The importance
of ARID1B function in normal neural development is
underscored by the causal role of de novo ARID1B mutations
in the congenital syndrome Coffin–Siris, as these patients dis-
play neurodevelopmental deficits (Santen et al. 2012).
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From the core constituents of the mammalian SWI–
SNF complex, the central ATPase, either represented by
BRG1 (SMARCA4) or BRM (SMARCA2), is the critical
driving force to alter nucleosome positioning using energy
derived from ATP hydrolysis. While, in many tumor en-
tities, BRG1 is known as a tumor suppressor, it may also
serve as key driver of an oncogenic expression program,
as illustrated by the study of Shi et al. showing that BRG1
in acute myeloid leukemia is required to sustain MYC
expression (Shi et al. 2013). In NB, high BRG1 levels
are associated with poor patient prognosis, pointing to-
wards its potential as a novel therapeutic target (Jubierre
et al. 2016).
Core regulatory circuits in neuroblastoma
development
Recently, super-enhancer-driven core regulatory circuits
have been defined that underlie NB development, further
illuminating the complex biology of this disease. One of
the fundamental driving forces in epigenetic reprogramming
has been linked to the activity of so-called super-enhancers
(SEs) or clustered enhancers (see Fig. 1). These are the main
control elements coupled to genes encoding master tran-
scription factors defining cellular identity, and are typically
characterized by binding of a multi-factorial regulatory com-
plex (Pott and Lieb 2015; Heinz et al. 2015) and a very high
density of the enhancer-associated histone modifications,
H3K27ac and H3K4me1, that mark high chromatin accessi-
bility of these regions. Key players at SE sites include
Mediator, RNA Pol II, CBP-p300 and a plethora of chroma-
tin modifiers, with a prominent role for SWI–SNF complex
components and the ‘bromodomain and extra-terminal mo-
tif’ (BET) protein family member BRD4 (see Fig. 1) (Hnisz
et al. 2013). The recruitment of BRD4 occurs through its
capability of recognizing and binding of acetylated histones
and its direct interaction with the Mediator complex (Pott
and Lieb 2015), ultimately facilitating both transcriptional
activation and elongation (Li 2002). Tumor cells typically
exploit the power of this specific class of regulatory ele-
ments to aberrantly boost the expression of oncogenes driv-
ing the major cancer hallmark dependencies (Hnisz et al.
2013; Whyte et al. 2013).
A first example of a SE-driven transcription factor in
NB is LMO1 (Oldridge et al. 2015), with oncogene addic-
tion driven by a single nucleotide polymorphism (SNP),
previously found as a germline SNP in a neuroblastoma
GWAS study, residing in a super-enhancer identified in
the first exon of LMO1 and serving as a critical determi-
nant for GATA3 binding to the SE site. Besides polymor-
phisms, chromosomal rearrangements involving super-
enhancer sites form another mechanism for aberrant gene
activation. Through whole-genome sequencing of 75 high-
risk neuroblastoma cases, Valentijn and co-workers recent-
ly identified that rearrangements involving the TERT gene
(Peifer et al. 2015) comprise about 23% of high-risk NB
cases, with half of those cases bearing a translocation lead-
ing to SE hijacking (Valentijn et al. 2015).
Although the majority of gene expression programs in-
volves many different transcriptional regulators, it has
been shown that only a handful of them, denominated as
core transcription factors, define the framework of cell-
specific networks (Saint-Andre et al. 2016), with their tar-
get genes marked by SE sites. These core regulators, of
which the expression is also SE-driven, work within a con-
stellation of a ‘core regulatory circuitry’, in which they
also regulate one another expression (formation of an
auto-regulatory loop). These circuitries are also key in the
process of malignant transformation, involving essential
oncogenic factors. This concept was previously illustrated
by Sanda and colleagues in the context of acute T-cell
leukemia (Sanda et al. 2012), where TAL1 together with
GATA3 and RUNX1 forms a positive feed-forward loop
converging to drive MYB expression, in its turn activating
TAL1 complex target genes. More recently, Van Groningen
et al. (2017) identified super-enhancer-associated tran-
scription factor regulatory circuits underlying interconvert-
ible neuroblastoma cell states of the adrenergic versus mes-
enchymal type, with neuroblastoma tumors consisting of a
heterogeneous mixture of both cell types. Whereas
MEOX1/2 and SOX9 among others were identified as
master regulators driving the mesenchymal cell state,
GATA3 and HAND1 were found to support the adrenergic
state. Binding of these transcriptional regulators to their
own enhancer, as well as with the enhancers driving the
expression of the other core regulators driving that cell
state, enforces regulatory loops that sustain the required
identity program. In addition, switching between these
identities was shown to be supported by the plasticity of
the super-enhancer profi le underlying the actual
reprogramming from one state to the other. In a parallel
paper, Boeva et al. (2017) defined mainly PHOX2B as well
as HAND2 and GATA3 as the main module controlling the
sympathetic noradrenergic cell type in NB tumors, and
defined a second population of a neural crest cell-like pop-
ulation sustained by the FOS/JUN transcription factor fam-
ily of which the expression anticorrelates to the noradren-
ergic transcription factor module, with PHOX2B and AP-1
found to regulate the super-enhancer landscape of the two
respective cell types. In MYCN-amplified NB tumors, the
neural crest cell module was found to be repressed. Based
on an integrated landscaping of NB transcriptome and epi-
genome landscapes, these studies reveal tumor heterogene-
ity as a novel aspect to be taken into account in the ratio-
nalization of novel therapeutic strategies for NB patients.
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Long non-coding RNAs and chromatin
architecture dynamics in gene expression
regulation
The study on functional annotation of the non-coding genome
has yielded further insights into the complex epigenetic regu-
lation of gene transcription. In addition to miRNAs, implicat-
ed in negative regulation of mRNA stability or translation of
its target transcripts, long non-coding RNAs (lncRNAs) are a
newly emerging important class of non-coding RNAs (Goff
and Rinn 2015; Rinn and Chang 2012). While the function of
most lncRNAs is still unknown, organism complexity is
strongly correlated to the proportion of the genome that is
non-coding (Liu et al. 2013a, b). Of further notice, in contrast
to miRNAs, lncRNAs have been shown to display a wide
variety of mode-of-actions (Bartonicek et al. 2016). The di-
versity of their folding or structure is crucial to support the
interaction with protein complexes and the specific functions
that lncRNAs are able to execute (Yan et al. 2016). In addition,
recent discoveries have proven their cell-type-specific expres-
sion, with important implications both in normal development
and during malignant transformation (Haemmerle and
Gutschner 2015) and thereby influencing various processes
such as genomic stability, cell proliferation and survival
(Huarte 2015).
Further, given the tissue-specific expression pattern of
many lncRNAs, they may represent important and powerful
biomarkers in diagnosis and monitoring of disease and are
currently being scrutinized to that end. This has been illustrat-
ed in prostate cancer where researchers identified lncRNA
PCA3 as being highly prostate-specific (Ronnau et al. 2014).
As a further consequence, lncRNAs can act as suitable thera-
peutic targets as their specific expression will avoid unwanted
toxic side effects in normal tissues (Gloss and Dinger 2016),
as illustrated by the identification of the melanoma-specific
lncRNA SAMMSON (Leucci et al. 2016). Taken together, it
can be expected that a better understanding of the previously
so-called ‘dark matter’ of the genome will have a profound
impact on our understanding of the complex regulation of
various cellular processes, including replication, transcription,
splicing, DNA repair and chromatin conformation. Together
with steadily evolving opportunities for genome editing and
RNA therapeutics, a new era of revolutionized targeted thera-
py is now emerging.
Just like protein-coding genes, lncRNAs can serve as bio-
markers for prognosis as well as diagnosis. Pandey et al.
(2014) identified a signature of 24 unannotated lncRNAs that
allows the discrimination between low- and high-risk NB
cases, with NBAT-1 as a top-candidate novel biomarker for
patient survival. In high-risk NB tumors, the NBAT-1 locus
is silenced by DNA methylation. In addition, a single nucle-
otide polymorphism (SNP) on 6p22 was shown to also signif-
icantly affect NBAT-1 expression. Functionally, NBAT-1 is
acting as a tumor suppressor through its interaction with the
PRC2 component EZH2 (see Fig. 1), silencing the expres-
sion of, e.g., SOX9. Similar to NBAT-1, another risk-
associated SNP mapping on 6p was associated with the locus
encoding the lncRNACASC15-S (Russell et al. 2015), with its
low expression also linked to poor patient prognosis.
Similarly, loss of GAS5 lncRNA expression is also a poor
prognostic marker in NB, as recently reported, in line with
previously observed marked reduction of GAS5 levels in ag-
gressive breast and gastric cancer. Loss of this tumor suppres-
sor lncRNA is mainly contributing to malignant transforma-
tion through the induction of p53 signaling leading to a cell
cycle arrest (Mazar et al. 2017). Although no differential
GAS5 expression could be observed between MYCN-
amplified versus non-amplified NB cases, GAS5 splice vari-
ants may be different between the two groups.
One of the best characterized lncRNAs so far implicated in
cancer is MALAT1, involved in many tumor types such as
prostate, ovarian and colorectal cancer. Very recently, Bi
et al. (2017) described the functional implication of
MALAT1 as a novel oncogene in NB development through
its positive regulation of AXL expression, thereby promoting
the invasive and migration potential of NB cells. Poor
prognosis of NB patients is often linked to MYCN
amplification, but in this same region Liu et al. (2014) also
identified lncUSMycN and the MYCN antisense transcript
NCYM to be co-amplified. Mechanistically, the lncRNA
lncUSMycN upregulates NCYM expression followed by its
binding to the RNA-interacting protein NonO, thereby upreg-
ulating MYCN expression (Liu et al. 2016). Another MYCN
upstream regulatory lncRNA is MYCNOS (chr2p24). To this
end, the MYCNOS transcript binds to CTCF (see Fig. 1), fa-
cilitating its association to the MYCN promotor region,
resulting in its transcriptional upregulation. Sahu et al. applied
an integrative analysis of lncRNA expression data determined
by either micro-array or RNA-sequencing of primary NB
cases. From the 51 lncRNA candidates derived from the
RNA-seq dataset, only 6 were overlapping with those deter-
mined as differentially expressed between the two groups,
among others the lncRNA SNHG1 (Sahu et al. 2016). This
study revealed a positive correlation between SNHG1 and
MYCN expression levels, with high SNHG1 levels corre-
sponding with poor disease outcome, and, if co-expressed
with the protein-coding gene TAF1D, a potential interaction
effect may be observed on patient outcome.
Deregulated 3D nuclear architecture in NB
The chromatin landscape is physically distributed yet func-
tionally connected in the three-dimensional nuclear space.
To this end, a modular organization takes place into three-
dimensional folds of so-called ‘topologically associating
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domains’ (TADs) that form in a cell-type specific manner
(Ciabrelli and Cavalli 2015). The TAD borders form an insu-
lated neighborhood and are evolutionary conserved. This or-
ganization involves several architectural proteins, with the
‘CCCTC binding factor’ (CTCF) as the well-known insulator
protein that recruits cohesins to stabilize the TAD borders. The
occurrence of CTCF at TAD borders comprises only 15% of
genome-wide CTCF binding, and the majority is comprised
within TADs where CTCF instructs proper enhancer–promot-
er interactions (Symmons et al. 2014). Disruption of these
insulated neighborhoods can lead to aberrant activation of
proto-oncogenes within a certain TAD, through interaction
with previously inaccessible enhancer regions outside the
TAD region and can be a consequence of several genomic
insults. In gliomas, hypermethylation of the CTCF binding
sites are shown to disrupt the insulation of the PDGFRA
proto-oncogene from an enhancer region, leading to its aber-
rant activation (Flavahan et al. 2016). Besides DNA methyla-
tion, insulated neighborhoods can also be distorted as a con-
sequence of genetic aberrations. A prototypical example is the
identification of microdeletions in acute T-cell leukemia,
perturbing the CTCF borders of a TAD and thus presenting
a novel mechanism to drive TAL1 or LMO2 overexpression
(Hnisz et al. 2016). In NB, the studies of Peifer et al. (2015)
and Valentijn et al. (2015), as previously discussed, link chro-
mosomal rearrangements to TAD distortions, ultimately
resulting in increased TERT expression associated with high-
risk NB tumor development.
CTCF plays a key role in normal neuronal development
(Hirayama et al. 2012) and has been previously described in
NB as one of the main targets of the tumor suppressormiRNA-
34a (itself a known MYCN target gene in NB development)
(De Antonellis et al. 2014). Zhao et al. (2016) identified CTCF
through an integrative data-mining approach of transcriptome
and ChIP-sequencing as a novel driver ofMYCN expression in
NB cells (as stated previously to be facilitated by its interac-
tion with the previously discussed non-coding RNA
MYCNOS), thereby serving as a driving force for neuroblas-
toma progression.
Towards drugging of the NB epigenome
Targeting DNA methylation
The dynamic and reversible character of the epigenome, as
well as its cancer- and cell-type-specific signature, make it a
very attractive target for therapy. Agents that modulate DNA
methylation, like the DNA methyltransferase inhibitor 5-aza-
2-deoxycytidine, have been previously shown to be effective
in the context of NB, both in vitro and in vivo, for reactivation
of tumor suppressor genes like ‘thrombospondin-1 (THBS1)’
and ‘heat-shock protein 47’ (HSP47) (Yang et al. 2003, 2004).
HDAC inhibition - tumor suppressor re-activation
Although it was initially anticipated that pharmacological in-
hibition of HDAC enzymes for cancer treatment would evoke
toxicity towards normal cells (and thus elicit strong side-ef-
fects), the rationale for the introduction of HDAC inhibitors in
cancer therapy regimens has been proven successful with
promising antitumor effects in clinical trials due to their very
high levels in tumors compared to normal cells, thereby cre-
ating a therapeutic window. In NB, as in several other cancers,
HDAC inhibition leads to p21 upregulation, thereby inducing
antiproliferative effects (Oehme et al. 2009a, b). Broad-
spectrum HDAC inhibitors (see Fig. 1) like vorinostat and
trichostatin A (TSA) have been shown to be effective in the
context of NB, but evoke unwanted side-effects. However, in
combination with other existing therapeutic strategies or
small-molecules, their potency can be increased. Mueller
and co-workers proposed the use of vorinostat to potentiate
the response of metastatic NB tumor cells to radiation therapy,
given that vorinostat interferes with the expression of key
DNA damage repair enzymes like RAD51 (Mueller et al.
2011). The potency of this combinatorial therapeutic strategy
is now being tested in clinical trials for various solid tumors.
Following a similar reasoning, Wang et al. showed synergistic
effects of combining the pan-HDAC inhibitor panobinostat
with DNA damage-inducing agents like cisplatin or etoposide,
partially related to repressive effects of panobinostat to CHK1
signaling (Wang et al. 2013). Waldeck and colleagues evalu-
ated the in vivo potential of panobinostat treatment against NB
tumors using the well-established TH-MYCN mouse model.
Long-term (9 weeks) exposure to panobinostat resulted in
strong antitumor regression without regrowth as a conse-
quence of induced tumor cell differentiation (Waldeck et al.
2016). In the course of potent combination strategies with
broad-spectrum HDAC inhibitors, the study of Kroesen
et al. (2016) provided a basis for clinical testing of combined
anti-GD2 antibody and vorinostat NB treatment, given that
vorinostat treatment leads to upregulation of surface GD2 ex-
pression on NB tumor cells and its modulation of the tumor
microenvironment to be more permissive for tumor-targeting
antibody therapy. Another example of this strategy was illus-
trated by Sholler et al. (2013) showing in vitro synergism
between the HDAC inhibitor abexinostat and the proteasome
inhibitor bortezomib, through upregulation of NOTCH signal-
ing and repression of MYCN expression, but mainly effective
through induction of reactive oxygen species induced apopto-
sis, an effect previously shown to underlie the potency of this
drug combination to combat Hodgkin lymphomas (Bhalla
et al. 2009). Now, more selective HDAC inhibitors are being
developed, such as HDAC8 specific inhibitors (see Fig. 1) that
have been shown to induce neurite formation and differentia-
tion in NB cells (Oehme et al. 2009a). In the same line,
HDAC5 would be an interesting therapeutic target given its
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capability to promote invasion/metastasis and suppress differ-
entiation (Fabian et al. 2016; Sun et al. 2014). Shahbazi and
co-workers identified that MYCN cooperates with HDAC2,
itself a target of MYCN (Marshall et al. 2010), to silence
TP53INP1 expression in NB leading to reduced p53 activa-
tion (Shahbazi et al. 2014). Frumm and co-workers discov-
ered, through a chemical probing approach for compounds
that can induce NB cell differentiation, the selective
HDAC1/2 inhibitor BRD8430 (Frumm et al. 2013).
Furthermore, this study provided evidence for synergism of
BRD8430 with cis retinoic acid as a pro-differentiation agent
by non-dependent mechanisms. In addition, ‘Sirtuin 2’
(SIRT2) inhibitors are also indicated for MYC(N) driven can-
cer entities like NB, given the role of SIRT2 inMYCN protein
stabilization and through repression of NEDD4 ubiquitin li-
gase expression (Liu et al. 2013a, b). Ling et al. showed that
the potency of HDAC inhibitors such as vorinostat can be
increased by a combined treatment with transamidation acti-
vators, based on the rationale that HDAC inhibitors like
SAHA lead to increased express ion of speci f ic
transglutaminase enzymes, rendering tumor cells less sensi-
tive to their cytotoxic effects (Ling et al. 2012).
Targeting oncogenes and tumor dependency genes
through interference with the epigenetic
transcription machinery
As mentioned above, the cancer epigenome landscape dic-
tates a transcriptional regulatory network. This represents a
druggable vulnerability as nicely illustrated by Veschi et al.
(2017). Shahbazi et al. (2016) recently described that
MYCN-amplified tumors are particularly sensitive to
‘BET bromodomain inhibitors (see Fig. 1), given that
BRD4 inhibition leads to a general downregulation of the
MYCN downstream transcriptional network (Puissant
et al. 2013). Moreover, the central role of MYCN in neu-
roblastoma oncogenesis with 25% of all primary cases har-
boring a MYC(N) amplification, but with limited expres-
sion in other mature tissues, makes it a very attractive tar-
get in neuroblastoma treatment. Interestingly, it was shown
that JQ1, besides a consensus gene expression signature,
also evokes a gene signature uniquely regulated in neuro-
blastoma, including genes for neuronal cell identity, e.g.,
PHOX2B. Recently emerging studies have proved that JQ1
is a very potent tool compound for promising synergistic
drug combinations. Shahbazi and co-workers identified
JQ1-panobinostat as a drug combination that could serve
as a very potent approach for treatment of high-risk NB
cases, given their synergistic downregulation of MYCN
and LIN28B expression levels (Shahbazi et al. 2016).
Besides JQ1, other BET inhibitors have also been shown
to be very potent to kill NB cells, such as I-BET726,
through suppression of apoptosis and MYCN downstream
signaling (Wyce et al. 2013). A more pre-clinically potent
BET inhibitor, OTX015, has recently been developed and
proven its efficacy both in murine and human MYCN-
driven in vivo tumor models (Henssen et al. 2016).
A further approach to target this transcriptional network
was published by Chipumuro et al. (2014). This paper started
from the rationale that cycles of transcription initiation and
elongation are particularly dependent on the action of specific
cyclin-dependent kinases (CDKs), with CDK7 as one of the
most prominent members implicated in this process. In this
respect, they reasoned that hampering of MYC(N)-driven
transcriptional amplification could be an interesting feature
to exploit for therapeutic purposes. The expression of
MYC(N) is in large part driven by an associated SE site and
so particularly sensitive to interference to perturbations at the
transcriptional level. In this way, they showed that pharmaco-
logical inhibition of CDK7 activity using the small molecule
THZ1 leads to selective targeting of MYC(N)-amplified NB
linked to its transcriptional interference inflicted to SE-linked
oncogenes like MYCN.
Epilogue
As recently proposed, epigenetic plasticity and resistance are
essential aspects forging the cancer cell phenotype and they
are logically interconnected with the hallmarks of cancer cells
(Hanahan and Weinberg 2011).We have summarized the var-
ious layers of epigenetic (re)wiring during neuroblastoma tu-
mor formation and how those insights can be exploited for the
improvement of patient diagnosis and prognosis, and the de-
velopment of innovative and targeted treatment protocols.
Future efforts should also be focusing on circumvention of
potential resistance mechanisms and prevention of relapse,
given that epigenetic processes also support tumor cell escape
to drugging effects and host immune surveillance (Frumm
et al. 2013). Given that, as for chemotherapy, novel therapies
using single compounds are destined to lead to treatment re-
sistance, new combinatorial approaches including epigenetic
drugs, together with other established treatment protocols like
chemotherapy or immunotherapy, are considered as the future
path towards more successful treatment. Detailed epigenomic
landscaping of NB tumor cells can therefore be expected to
become an essential part of the diagnostic genetic work up,
given that about 20% of mutations in pediatric cancers are
found in genes encoding key epigenetic regulators (Huether
et al. 2014). These genomic changes contribute to major
changes in the epigenetic lands of tumor cells that also play
a significant role during malignant transformation. Integrative
epigenome analysis will therefore be key to better characterize
tumors in a diagnostic setting and will further open novel
opportunities for therapeutic intervention. One could think
of the possibility to perform whole-genome bisulfite
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sequencing on circulating tumor DNA obtained from liquid
biopsies to integrate methylation profiling in a diagnostic set-
ting or ATAC-seq to obtain chromatin accessibility profiles on
primary patient-derived cells.
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